Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Halma plc (HLMAF)
Amersham, BU, GB
Established in 1894 and based in Amersham, UK, Halma plc is a global group of companies delivering innovative technological products and services across three primary areas: safety, health, and environmental protection. These operations are structured into three distinct segments: Safety, Environmental & Analysis, and Medical. The Safety division focuses on preventing harm and managing risk; its offerings include advanced fire detection and suppression systems, secure elevator operation technologies, various security sensors, solutions for managing human and vehicular traffic, specialized interlocks to ensure safe critical process control, and protective measures against explosions and corrosion. This segment caters to a broad range of industries, such as elevator safety, fire management, access control for industrial settings, secure storage and material transfer, and general people and vehicle movement. Within the Environmental & Analysis segment, Halma develops and supplies technologies for understanding and protecting our surroundings, encompassing sophisticated optical and imaging systems, comprehensive monitoring solutions for water, air, and various gases, devices for identifying dangerous gases and assessing air quality, and advanced systems for water purification and analysis. Key markets for this segment include optical diagnostics, water management, gas sensing, and overall environmental observation. The Medical division is dedicated to supporting healthcare and life sciences; it delivers essential fluidic components for medical diagnostic equipment and OEMs, along with laboratory instruments and systems that generate vital patient health data to guide treatment decisions. This segment also provides technologies and solutions that facilitate in-vitro diagnostics, accelerate life-science research and development, and improve patient outcomes across diverse clinical fields. Its primary markets are life sciences, health evaluation, and therapeutic interventions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.59% | -15.53% | -13.84% | +1.22% | +12.18% | +7.98% | +26.41% | +73.40% | +34.07% | +280.89% | +2,222.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Conglomerates: +6.1%+15.2% ★ Q1'26: +24.4% (vs Q1'24)
-
EPS growth Conglomerates: +16.9%+26.9% ★ Q1'26: +22.5% (vs Q1'24)
-
FCF margin FCF growth · Conglomerates: +35.9%+14.2% Q1'26: +18.4% (vs Q1'24)
-
EBIT margin Conglomerates: +9.0%+20.4% ★ Q1'26: +20.0% (vs Q1'24)
-
ROIC Conglomerates: +4.7%+13.6% ★ Q1'26: +27.3% (vs Q1'24)
-
Share dilution Conglomerates: +0.0%+0.0% Q1'26: +0.2% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Conglomerates: 1.28×1.39× ★ Q1'26: 0.67× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 1 EPS Ana. |
Mar 2027 7 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
726.13M
est: 1.07B (-32.3%)
|
807.81M
est: 1.14B (-29.4%)
|
961.66M
est: 1.19B (-19.2%)
|
1.08B
est: 1.48B (-27.3%)
|
1.21B
est: 1.58B (-23.1%)
|
1.34B
est: 1.65B (-18.9%)
|
1.32B
est: 1.82B (-27.6%)
|
1.53B
est: 1.97B (-22.4%)
|
1.85B
est: 2.21B (-16.3%)
|
2.03B
est: 1.99B (+2.0%)
|
2.25B
est: 2.21B (+1.6%)
|
2.58B
2.55B – 2.61B
+16.4% YoY
|
2.95B
2.92B – 2.99B
+14.6% YoY
|
3.21B
3.17B – 3.25B
+8.6% YoY
|
3.26B
3.23B – 3.31B
+1.8% YoY
|
| EBITDA |
178.87M
est: 258.92M (-30.9%)
|
187.39M
est: 276.41M (-32.2%)
|
224.04M
est: 287.52M (-22.1%)
|
243.20M
est: 357.24M (-31.9%)
|
282.30M
est: 380.30M (-25.8%)
|
320.60M
est: 398.41M (-19.5%)
|
353.30M
est: 439.54M (-19.6%)
|
373.40M
est: 474.59M (-21.3%)
|
410.60M
est: 534.67M (-23.2%)
|
475.50M
est: 481.51M (-1.2%)
|
537.30M
est: 534.32M (+0.6%)
|
621.83M
615.07M – 630.01M
+16.4% YoY
|
712.71M
704.97M – 722.08M
+14.6% YoY
|
774.11M
765.71M – 784.30M
+8.6% YoY
|
788.24M
779.68M – 798.61M
+1.8% YoY
|
| EBIT |
138.19M
est: 197.41M (-30.0%)
|
142.49M
est: 210.74M (-32.4%)
|
166.39M
est: 219.21M (-24.1%)
|
180.90M
est: 272.37M (-33.6%)
|
216.10M
est: 289.95M (-25.5%)
|
235.90M
est: 303.76M (-22.3%)
|
263.00M
est: 335.11M (-21.5%)
|
312.70M
est: 361.84M (-13.6%)
|
309.00M
est: 407.65M (-24.2%)
|
369.90M
est: 367.12M (+0.8%)
|
417.00M
est: 407.38M (+2.4%)
|
474.10M
468.95M – 480.34M
+16.4% YoY
|
543.39M
537.48M – 550.53M
+14.6% YoY
|
590.21M
583.79M – 597.97M
+8.6% YoY
|
600.97M
594.45M – 608.88M
+1.8% YoY
|
| Net Income |
104.00M
est: 116.74M (-10.9%)
|
108.84M
est: 128.29M (-15.2%)
|
129.69M
est: 150.54M (-13.9%)
|
154.20M
est: 164.99M (-6.5%)
|
169.80M
est: 189.98M (-10.6%)
|
184.40M
est: 213.16M (-13.5%)
|
203.40M
est: 212.64M (-4.3%)
|
244.40M
est: 240.22M (+1.7%)
|
234.50M
est: 283.54M (-17.3%)
|
268.80M
est: 308.15M (-12.8%)
|
296.40M
est: 349.04M (-15.1%)
|
428.50M
422.45M – 435.83M
+22.8% YoY
|
493.48M
486.51M – 501.92M
+15.2% YoY
|
549.59M
541.82M – 558.99M
+11.4% YoY
|
574.45M
566.34M – 584.28M
+4.5% YoY
|
| SGA |
246.20M
est: 342.56M (-28.1%)
|
278.99M
est: 365.70M (-23.7%)
|
343.24M
est: 380.40M (-9.8%)
|
385.50M
est: 472.64M (-18.4%)
|
381.20M
est: 503.15M (-24.2%)
|
432.10M
est: 527.11M (-18.0%)
|
412.50M
est: 581.52M (-29.1%)
|
484.70M
est: 627.91M (-22.8%)
|
614.50M
est: 707.40M (-13.1%)
|
636.10M
est: 637.06M (-0.2%)
|
724.10M
est: 706.93M (+2.4%)
|
822.70M
813.77M – 833.53M
+16.4% YoY
|
942.94M
932.70M – 955.34M
+14.6% YoY
|
1.02B
1.01B – 1.04B
+8.6% YoY
|
1.04B
1.03B – 1.06B
+1.8% YoY
|
| EPS |
0.27
est: 0.31 (-12.3%)
|
0.29
est: 0.34 (-14.3%)
|
0.34
est: 0.40 (-14.4%)
|
0.41
est: 0.44 (-5.8%)
|
0.45
est: 0.50 (-10.2%)
|
0.49
est: 0.56 (-12.8%)
|
0.54
est: 0.56 (-3.7%)
|
0.65
est: 0.63 (+2.6%)
|
0.62
est: 0.75 (-17.1%)
|
0.71
est: 0.81 (-12.6%)
|
0.78
est: 0.92 (-15.3%)
|
1.13
1.11 – 1.15
+22.8% YoY
|
1.30
1.28 – 1.32
+15.2% YoY
|
1.45
1.43 – 1.47
+11.4% YoY
|
1.51
1.49 – 1.54
+4.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-10 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-09 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-08 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-05 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-03 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-02 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-01 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marc Arthur Ronchetti | Group Chief Executive Officer, Member of Executive Board & Executive Director | 4M | male |
| Jennifer Ward | Group Talent, Culture & Communications Executive, Member of Executive Board and Executive Director | 2M | female |
| Carole Jean Cran | Chief Financial Officer, Member of Executive Board & Executive Director | 587.4K | female |
| Charlene Lim | Group General Counsel & Member of Executive Board | — | female |
| Charles King | Head of Investor Relations | — | male |
| Constance F. Baroudel | Chief Sustainability Officer, Sector Chief Executive Officer of Env. & Analysis and Member of Executive Board | — | female |
| Funmi Adegoke | Chief Executive Officer of Safety Sector & Member of Executive Board | — | female |
| Rob Lewis | Divisional Chief Executive of Environmental & Analysis Sector | — | male |
| Aldous Wong | President of Halma Asia Pacific, Adviser & Member of Executive Board | — | male |
| Steve Brown | Sector Chief Executive of Healthcare & Member of Executive Board | — | male |
| Bill Stoval | Chief Executive Officer of Divisional | — | male |
| Catherine E. Michel | Chief Technology Officer & Member of Executive Board | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HLMAF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
